Cellectar Biosciences updates interim overall survival data from CLR 131 trial
Cellectar Biosciences updates interim overall survival, or OS data from the company's ongoing Phase 1b clinical trial evaluating CLR 131 for the treatment of relapsed/refractory multiple myeloma, or MM. The results to date show that OS is currently at 19.4 months. Cellectar continues to monitor these patients and intends to update OS results as data become available. All 15 patients from the Phase 1b, single-dose cohorts were heavily pretreated, receiving an average of 5 previous lines of multidrug therapy including anti CD38, immunomodulating drugs and proteasome inhibitors. All patients were relapsed or refractory to at least one proteasome inhibitor and IMiD. Most patients presented with advanced stage 2 or 3 disease and 67% had previously received at least 1 stem cell transplant.